SpineGuard announced that its full year revenue for the fiscal year 2013 is $7.6 million, up from its full year revenue for fiscal year 2012, which was $6.4 million.
The company recorded a net loss of $5.8 million for the full year 2013, up from the net loss it recorded for full year 2012, which was $5.3 million.
The company sold 6,308 of its PediGuard units in 2013, as compared to the 5,225 units sold for the full year 2012. Also, in 2013, the company received 510(k) clearance from the U.S. Food and Drug Administration for its new XS Classic and XS Curved PediGuard versions as well as approval in Russia for the entire PediGuard bone-monitoring platform.
The company announced the limited-series prelaunch of the Classic PediGuard XS and Curved PediGuard XS miniaturized versions as well as the development of new applications of the PediGuard platform.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws